A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference26 articles.
1. The European mesothelioma epidemic;Peto;Br. J. Cancer,1999
2. Prognostic factors in patients with pleural mesothelioma;Curran;J. Clin. Oncol.,1998
3. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B;Herndon;Chest,1998
4. Advances in the treatment of malignant pleural mesothelioma;Sterman;Chest,1999
5. Malignant pleural mesothelioma;Boutin;Eur. Respir. J.,1998
Cited by 31 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Current Management and Future Perspective in Pleural Mesothelioma;Cancers;2022-02-18
2. Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression;Journal of Thoracic Oncology;2020-05
3. Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma;Asbestos and Mesothelioma;2017
4. Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma;European Journal of Cancer;2012-11
5. Mesotheliomas;Textbook of Uncommon Cancer;2012-09-20
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3